FRANKLIN, Tenn.--(BUSINESS WIRE)--Sept. 14, 2006--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that Company president and CEO, Dr. Samuel E. Lynch, along with his co-authors, will be honored with the prestigious American Academy of Periodontology's R. Earl Robinson Regeneration Award for the scientific publication they authored entitled Platelet-derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level Gain: Results of a Large Multicenter Randomized Controlled Trial. The publication details the positive results of the pivotal trial for the Company's lead product GEM 21S(R), which was approved by the FDA in November 2005 for the treatment of periodontal disease and gingival recession. The award will be presented at the 92nd Annual Meeting of the American Academy of Periodontology (AAP) in San Diego, CA on Saturday, September 16, 2006.
